Fosamax for Paget's Disease: Dosing Protocol and Clinical Evidence

Is Alendronate Actually FDA-Approved for Paget's Disease?

Yes. Despite frequent categorization as "off-label," alendronate received explicit FDA approval for the treatment of Paget's disease of bone in 1995, the same year it was approved for osteoporosis [1]. The approved Paget's indication calls for 40 mg once daily for six months. This is a separate dosing regimen from the 10 mg daily or 70 mg weekly schedules used for postmenopausal osteoporosis. The confusion arises because most prescribers associate Fosamax exclusively with osteoporosis, and the 40 mg tablet is prescribed far less frequently.

The FDA-approved prescribing label lists Paget's disease as a distinct indication with its own dosing section [1]. The 2014 Endocrine Society Clinical Practice Guideline on Paget's Disease names alendronate as one of four bisphosphonates with adequate trial evidence for this condition, noting that "bisphosphonates are the mainstay of treatment" [2]. Patients searching for whether Fosamax can be used for Paget's disease should understand that this use carries full regulatory approval, not off-label status.

How Paget's Disease Dosing Differs from Osteoporosis Dosing

The dosing protocol for Paget's disease differs from osteoporosis treatment in three specific ways: total daily dose, treatment duration, and retreatment logic. These differences reflect the distinct pathophysiology of Paget's disease, which involves focal areas of accelerated and disordered bone remodeling rather than the generalized bone loss seen in osteoporosis [3].

For osteoporosis, alendronate is prescribed at 10 mg daily or 70 mg weekly on an ongoing, open-ended basis. For Paget's disease, the protocol is 40 mg once daily for a fixed six-month course [1]. The higher daily dose targets the intense osteoclastic activity in pagetic bone. After six months, treatment stops. The clinician then monitors serum alkaline phosphatase (SAP) at regular intervals. Retreatment is considered only if SAP rises back above normal reference ranges or if symptoms return [2].

This fixed-course approach matters. Paget's disease does not require lifelong suppression in most patients. A single six-month course of alendronate may maintain biochemical remission for years. In the key trial by Siris et al. (1996), patients who achieved SAP normalization maintained suppressed levels well beyond the treatment period [4].

Clinical Evidence for Alendronate in Paget's Disease

The registration trial that secured FDA approval compared alendronate 40 mg/day to etidronate 400 mg/day in 89 patients over six months [4]. Alendronate normalized SAP in 48% of patients versus 0% with etidronate (P<0.001). Mean SAP decreased by 73% in the alendronate group compared to 44% with etidronate. Bone-specific alkaline phosphatase, urinary hydroxyproline, and urinary deoxypyridinoline all showed greater reductions with alendronate.

A separate open-label extension study followed 78 alendronate-treated patients for up to 28 months. SAP normalization rates reached 66% in patients who had not achieved normal levels during the initial six-month course, and biochemical suppression persisted for over a year after discontinuation in most responders [5]. Pain scores also improved. The ASBMR review on Paget's disease confirmed that alendronate produces "significant and sustained decreases in biochemical markers of bone turnover" [6].

Dr. Ethel Siris, the lead investigator of the key alendronate-Paget's trial at Columbia University, stated: "Alendronate produced normalization of alkaline phosphatase in nearly half of patients in just six months, a result no prior oral agent had achieved in controlled study" [4].

Three specific statistics define alendronate's profile in Paget's disease:

1. SAP normalization: 48% at 6 months in the controlled trial (vs. 0% etidronate) [4]
2. Mean SAP reduction: 73% from baseline [4]
3. Extended normalization: 66% in open-label follow-up at 28 months [5]

Step-by-Step Dosing Protocol

The full dosing protocol, consistent with the FDA label and the Endocrine Society guideline, follows a structured sequence [1][2].

Pre-treatment assessment. Confirm the diagnosis with a combination of elevated SAP, compatible radiographic findings, and (if needed) bone scintigraphy. Check serum calcium and 25-hydroxyvitamin D levels. Correct any vitamin D deficiency before starting alendronate, because bisphosphonate-induced suppression of bone resorption in a vitamin D-deficient patient can precipitate hypocalcemia [2]. The Endocrine Society recommends repleting 25(OH)D to at least 20 ng/mL (50 nmol/L) before initiating treatment.

Dosing. Prescribe alendronate 40 mg once daily. The tablet must be taken first thing in the morning on an empty stomach with a full glass (8 ounces) of plain water. No food, drink, or other oral medication for at least 30 minutes after ingestion. The patient must remain upright (sitting or standing) for a minimum of 30 minutes to reduce esophageal irritation risk [1].

Calcium and vitamin D supplementation. Ensure the patient takes at least 1 to 000 mg of elemental calcium and 800 IU of vitamin D daily, but not within 30 minutes of the alendronate dose. Calcium supplements taken simultaneously will reduce alendronate absorption by chelation.

Duration. Six months. Do not extend beyond six months in the initial course. Do not switch to a weekly dosing format for Paget's disease; the 70 mg weekly tablet is approved only for osteoporosis [1].

Post-treatment. Discontinue alendronate after six months. Begin monitoring SAP every three to six months. No maintenance therapy is needed if SAP has normalized.

Monitoring and Treatment Response

Serum alkaline phosphatase is the primary biomarker for tracking Paget's disease activity and treatment response [2]. SAP correlates with the extent and metabolic activity of pagetic lesions, and it responds predictably to antiresorptive therapy.

A clinically meaningful response is defined as SAP returning to within the normal reference range (typically 35 to 130 U/L, though ranges vary by laboratory). Some experts track bone-specific alkaline phosphatase (BSAP) for greater specificity, particularly in patients with concurrent liver disease that may raise total SAP.

Draw SAP at baseline, then at months 3 and 6 during treatment. After completing the six-month course, recheck SAP every six months for two years, then annually. The 2014 Endocrine Society guideline recommends that "serum total alkaline phosphatase should be measured periodically, beginning 6 to 12 weeks after initiating treatment, until a nadir is reached" [2].

Watch for symptomatic improvement as well. Pagetic bone pain typically begins to decrease within the first three months of treatment. Hearing loss associated with skull involvement, however, responds poorly to bisphosphonate therapy even when biochemical markers normalize [3].

Radiographic reassessment is not routinely needed after treatment if SAP normalizes. For monostotic disease where SAP may remain within normal limits even during active disease, imaging may be the only reliable monitoring tool.

Alendronate vs. Other Paget's Disease Treatments

Several bisphosphonates carry evidence for Paget's disease. The choice between them involves potency, route of administration, and patient preference.

Zoledronic acid (Reclast, 5 mg IV). The HORIZON-PFT extension and the Reid et al. (2005) NEJM trial comparing a single 5 mg zoledronic acid infusion to risedronate 30 mg daily for 60 days in 357 patients demonstrated SAP normalization in 89% of zoledronic acid patients versus 58% with risedronate at 6 months (P<0.001) [7]. Zoledronic acid is the most potent single-dose option and is preferred by many specialists for moderate-to-severe Paget's disease.

Risedronate (Actonel, 30 mg/day for 60 days). Also FDA-approved for Paget's disease. Head-to-head data against alendronate are limited, but cross-trial comparisons suggest similar SAP normalization rates in the 50% to 60% range.

Etidronate (Didronel, 400 mg/day for 6 months). The first bisphosphonate approved for Paget's. Less effective than alendronate in direct comparison [4]. Associated with osteomalacia risk at higher doses. Rarely used today.

Calcitonin. Injected salmon calcitonin was a standard treatment before bisphosphonates became available. SAP reductions average only 40% to 50%, without normalization in most cases [3]. It has been replaced by bisphosphonates as a first-line therapy.

Alendronate occupies a middle position: more effective than etidronate, easier to administer than IV zoledronic acid, and available at low cost as a generic. For patients who prefer an oral option and have mild-to-moderate disease, alendronate 40 mg daily for six months remains a reasonable first choice.

Side Effects and Safety Considerations

Upper gastrointestinal symptoms are the primary concern with oral alendronate. Esophagitis, esophageal ulceration, and gastric irritation occur at higher rates when patients fail to follow the strict upright-posture and fasting instructions [1]. The six-month Paget's protocol at 40 mg/day carries a higher cumulative GI exposure than the osteoporosis regimen, making adherence to administration guidelines especially important.

Musculoskeletal pain occurs in a subset of patients starting bisphosphonate therapy. The FDA issued a safety communication in 2008 noting that severe musculoskeletal pain can appear days to months after bisphosphonate initiation and typically resolves after discontinuation [8].

Osteonecrosis of the jaw (ONJ) has been reported with oral bisphosphonates, though the risk is substantially lower than with high-dose IV bisphosphonate regimens used in oncology. A systematic review in the Journal of Bone and Mineral Research estimated the incidence of ONJ with oral bisphosphonates at approximately 1 in 10,000 to 1 in 100,000 patient-years [9]. Dental evaluation before initiating the six-month course is prudent, particularly if invasive dental procedures are planned.

Atypical femoral fractures have been associated with long-term bisphosphonate use (typically beyond 5 years), but this risk is less relevant for the time-limited Paget's disease protocol. A single six-month course does not carry the same cumulative exposure concern.

Hypocalcemia can occur if vitamin D deficiency is not corrected before treatment. Measure and replete 25(OH)D before prescribing. Symptoms include muscle cramps, paresthesias, and (in severe cases) cardiac arrhythmia.

When to Consider Retreatment

Not all patients will need a second course. The decision depends on biochemical relapse, symptom recurrence, or both.

Retreatment is appropriate when SAP rises back above the upper limit of normal after an initial response, when pagetic symptoms (bone pain, warmth over affected bone, new deformity) return, or when the patient faces elective orthopedic surgery on pagetic bone and pre-operative suppression of disease activity is desired [2]. The Endocrine Society recommends "retreatment with a potent bisphosphonate if alkaline phosphatase rises above normal after an initial therapeutic response" [2].

Some clinicians adopt a more aggressive retreatment threshold, intervening when SAP rises more than 25% above its post-treatment nadir even if it remains within the normal range. This approach lacks strong trial support but is biologically plausible in patients with initially very high disease activity.

The retreatment regimen is the same: alendronate 40 mg daily for six months. Alternatively, patients who do not normalize with alendronate may be switched to a more potent agent such as zoledronic acid 5 mg IV [7]. There is no established maximum number of treatment courses, though cumulative bisphosphonate exposure should be weighed against the theoretical risks of ONJ and atypical fractures with repeated courses over many years.

Asymptomatic patients with normal SAP after a treatment course require no retreatment, regardless of unchanged radiographic findings. Paget's disease is a metabolic condition, and the goal of therapy is biochemical and symptomatic control rather than radiographic resolution of established pagetic bone changes [3].